Annual ‘Honor Roll’ released, recognizing best children’s hospitals in the US

U.S. News & World Report has shared its annual ranking of the top children’s hospitals in the U.S., after an analysis of how well each safely and effectively provided care for young people in their respective regions of the country. 

The 10 healthcare institutions make up what the publication calls its 2024-2025 Best Children's Hospitals Honor Roll, which equally recognizes each hospital for their exceptional delivery of quality care.

U.S. News & World Report and nonprofit research group RTI International worked together on the rankings, reviewing data on patient outcomes from more than 100 hospitals, zooming in on care delivery for children in need of 11 specialty health services, including pediatric cancer, cardiology, neurology, orthopedics and others. 

For the first time, the outlet included juvenile behavioral health in its analysis. 

“This year’s inclusion of behavioral health as a new specialty is significant, as one in five U.S. children has a mental, emotional, behavioral or developmental disorder, according to the Department of Health and Human Services,” Ben Harder, chief of health analysis and managing editor at U.S. News & World Report, said in a statement. “U.S. News is responding to the growing mental health crisis among America’s youth by giving families a valuable source of behavioral health data as part of our increasingly comprehensive view of pediatric care.”

The 10 hospitals on the list earned a top mark in a specialty or for general pediatric care in its region. They are listed in alphabetical order, with notations added for why each earned its place on the list. 

Best Children’s Hospitals in the U.S. for 2024-2025:

The full list, including rankings by region and 11 different pediatric specialties, can be found here

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.